Co-administration of MDR1 and BCRP or EGFR/PI3K inhibitors overcomes lenvatinib resistance in hepatocellular carcinoma

Dawei Sun(Jinan University), Jiahong Dong(Beijing Tsinghua Chang Gung Hospital)
Frontiers in Oncology
September 8, 2022
Cited by 43


Related Papers